Our meta-analysis suggests that, for patients with EGFR-mutated NSCLC who have progressed on TKI therapy, the amiva-lazer-chemo regimen is the preferred option for delaying disease progression at both the study and individual patient levels. Here, EGFR is linked to non-small cell lung carcinoma.